Alcohol Tobacco and Drug Use and Abuse
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Nottinghamshire Primary Care Alcohol Misuse Guidelines
Nottinghamshire Primary Care Alcohol Dependence Guidelines V5.2 Last reviewed: April Review date: August 2021 2022 Title Nottinghamshire Primary Care Alcohol Dependence Guidelines Version 5.2 Lead - Dr Stephen Willott, GP Windmill Practice, Nottingham; Clinical Lead for alcohol misuse, Nottingham Recovery Network and Public Health Department, Nottingham City Council Author / Tanya Behrendt, Senior Pharmacist (Nottingham City Locality), NHS Nottingham and Nottinghamshire CCG Nominated Apollos Clifton-Brown, Operational Manager, Nottingham Recovery Network Dr David Rhinds, Consultant Addictions Psychiatrist, Nottinghamshire Healthcare NHS Foundation Trust Lead Dr Kaanthan Jawahar, ST6 Old Age Psychiatry, Derbyshire Healthcare NHS Foundation Trust Hannah Godden, Mental Health Interface and Efficiencies Pharmacist, Nottinghamshire Healthcare NHS Foundation Trust/ NHS Nottingham and Nottinghamshire CCG Jill Theobald, Interface Efficiencies Pharmacist, NHS Nottingham and Nottinghamshire CCG Approval Date August 2019 Review Date August 2022 Section Contents Page Number i. Summary 2 1. Introduction 4 2. Scope 5 3. Aims of Community Detoxification 5 4. Identifying suitable patients 5 5. Medical risks of community detoxification 6 6. Risk reduction 6 7. Record keeping 7 8. Equipment 7 9. Preparation for home detoxification 7 10. Medication 8 11. Relapse prevention/Follow up 8 12. Reducing alcohol consumption in people with alcohol dependence 9 13. Potentially difficult situations 10 14. References and version control 10 Appendix A Diagnostic Criteria -
The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines World Health Organization F10 - F19 Mental and behavioural disorders due to psychoactive substance use Overview of this block F10. – Mental and behavioural disorders due to use of alcohol F11. – Mental and behavioural disorders due to use of opioids F12. – Mental and behavioural disorders due to use of cannabinoids F13. – Mental and behavioural disorders due to use of sedative hypnotics F14. – Mental and behavioural disorders due to use of cocaine F15. – Mental and behavioural disorders due to use of other stimulants, including caffeine F16. – Mental and behavioural disorders due to use of hallucinogens F17. – Mental and behavioural disorders due to use of tobacco F18. – Mental and behavioural disorders due to use of volatile solvents F19. – Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances Four- and five-character codes may be used to specify the clinical conditions, as follows: F1x.0 Acute intoxication .00 Uncomplicated .01 With trauma or other bodily injury .02 With other medical complications .03 With delirium .04 With perceptual distortions .05 With coma .06 With convulsions .07 Pathological intoxication F1x.1 Harmful use F1x.2 Dependence syndrome .20 Currently abstinent .21 Currently abstinent, but in a protected environment .22 Currently on a clinically supervised maintenance or replacement regime [controlled dependence] .23 Currently abstinent, but receiving treatment with -
Karla Luciana Magnani
Karla Luciana Magnani ESTUDO MORFO-FUNCIONAL, BIOQUÍMICO E IMUNOHISTOQUÍMICO DO APARELHO RESPIRATÓRIO EM RATOS EXPOSTOS À FUMAÇA DO CIGARRO E AO ÁLCOOL Tese apresentada ao Programa de Pós-graduação em Bases Gerais da Cirurgia Faculdade de Medicina de Botucatu UNESP-SP para a obtenção de Título de Doutor Área de Concentração: Reparação, Regeneração e Transplante de Tecidos e Órgãos. Orientador: Dr Antônio José Maria Cataneo Co-orientadora: Dra Daniele Cristina Cataneo BOTUCATU 2009 FICHA CATALOGRÁFICA ELABORADA PELA SEÇÃO TÉCNICA DE AQUISIÇÃO E TRATAMENTO DA INFORMAÇÃO DIVISÃO TÉCNICA DE BIBLIOTECA E DOCUMENTAÇÃO - CAMPUS DE BOTUCATU - UNESP Bibliotecária responsável: Selma Maria de Jesus Magnani, Karla Luciana. Estudo morfo-funcional, bioquímico e imunohistoquímico do aparelho respiratório em ratos expostos à fumaça do cigarro e ao álcool / Karla Luciana Magnani. – Botucatu : [s.n.], 2009. Tese (doutorado) – Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, 2009. Orientador: Antônio José Maria Cataneo Co-orientadora: Daniele Cristina Cataneo Assunto CAPES: 40101126 1. Alcoolismo 2. Tabagismo 3. Pulmões - Doenças - Estudos experimentais CDD 618.39 Palavras chave: Alcoolismo; Apoptose; Estresse oxidativo; Ratos wistars; Tabagismo >$`:RVMQ : V%5 ]Q` IV :%61C1:` J: `V:C1<:M>Q RV : ]V_%1:5 HQI :'RV5 ]V`V0V`:JM:5]V`1 YJH1:V:GVRQ`1:?8 VR1HQ V : ]V_%1: : QRQ IV% `:I1C1:`V5 VI V]VH1:C :Q IV% ]:1 "%`1RV V 1IV` V :Q IV% I:`1RQ5 CV:JR`Q #QR`1$Q $V@15 _%V I:1 RQ _%V _%:C_%V` Q% `: ]VQ:IV:%61C1Q%J:HQJHC%>QRV :V :]:8$V@1 V:$`:RVMQ]Q`V -
Lung Morphology and Growth of Rats Exposed to Tobacco Smoke and Alcohol1 Estudo Morfológico Dos Pulmões E Crescimento De Ratos
4 – ORIGINAL ARTICLE MODELS, BIOLOGICAL Lung morphology and growth of rats exposed to tobacco smoke and alcohol1 Estudo morfológico dos pulmões e crescimento de ratos expostos à fumaça do cigarro e ao álcool Karla Luciana MagnaniI, Daniele Cristina CataneoII, Vera Luiza CapelozziIII, Julio DefaveriIV, Erica Nishida HasimotoI, Antônio José Maria CataneoV IFellow PhD degree, Postgraduate Program in General Basis of Surgery, Botucatu School of Medicine, UNESP, Sao Paulo-SP, Brazil. Acquisition and interpretation of data, manuscript writing. IIPhD, Assistant Professor, Division of Thoracic Surgery, UNESP, Sao Paulo-SP, Brazil. Conception and design of the study. IIIPhD, Associate Professor, Department of Pathology, University of Sao Paulo (USP), Brazil. Acquisition and interpretation of data. IVPhD, Associate Professor, Department of Pathology, UNESP, Sao Paulo-SP, Brazil. Acquisition and interpretation of data. VPhD, Chairman, Full Professor, Division of Thoracic Surgery, UNESP, Sao Paulo-SP, Brazil. Conception, design, intellectual and scientific content of the study. ABSTRACT PURPOSE: Investigate the morphological effects of chronic exposure to tobacco smoke inhalation and alcohol consumption on the lungs and on the growth of rats. METHODS: Sixty male Wistar rats were divided into four groups: control, tobacco, alcohol, tobacco + alcohol, for a period of study 260 days. Morphological analysis was conducted by optical and electron microscopy. Rat growth was investigated by measuring the snout-anus length, body mass index and body weight. RESULTS: The three groups exposed to the drugs presented lower growth and lower weight than the control group. The percentages of alveolitis, bronchiolitis and the mean alveolar diameter were greater, particularly in the groups exposed to tobacco smoke, but were not significantly different from the control group. -
Alcohol Withdrawal
Alcohol withdrawal TERMINOLOGY CLINICAL CLARIFICATION • Alcohol withdrawal may occur after cessation or reduction of heavy and prolonged alcohol use; manifestations are characterized by autonomic hyperactivity and central nervous system excitation 1, 2 • Severe symptom manifestations (eg, seizures, delirium tremens) may develop in up to 5% of patients 3 CLASSIFICATION • Based on severity ○ Minor alcohol withdrawal syndrome 4, 5 – Manifestations occur early, within the first 48 hours after last drink or decrease in consumption 6 □ Manifestations develop about 6 hours after last drink or decrease in consumption and usually peak about 24 to 36 hours; resolution occurs in 2 to 7 days 7 if withdrawal does not progress to major alcohol withdrawal syndrome 4 – Characterized by mild autonomic hyperactivity (eg, tachycardia, hypertension, diaphoresis, hyperreflexia), mild tremor, anxiety, irritability, sleep disturbances (eg, insomnia, vivid dreams), gastrointestinal symptoms (eg, anorexia, nausea, vomiting), headache, and craving alcohol 4 ○ Major alcohol withdrawal syndrome 5, 4 – Progression and worsening of withdrawal manifestations, usually after about 24 hours from the onset of initial manifestations 4 □ Manifestations often peak around 50 hours before gradual resolution or may continue to progress to severe (complicated) withdrawal, particularly without treatment 4 – Characterized by moderate to severe autonomic hyperactivity (eg, tachycardia, hypertension, diaphoresis, hyperreflexia, fever); marked tremor; pronounced anxiety, insomnia, -
Alcohol Responsibly and Ending Tobacco Use, Plus Caffeine - Dr
MHE-110 – Chapter Nine – Drinking Alcohol Responsibly and Ending Tobacco Use, plus Caffeine - Dr. Dave Shrock Chapter Nine Alcohol - an overview Alcohol and ending Tobacco Use 13th pp. 239-240; 12th pp. 232-223 • alcohol is the most widely used drug in the United (including caffeine) States • 86% of Americans consume alcohol 13th edition, pp. • 10% are heavy drinkers…who consume half of all the 241-269 alcohol produced 12th edition: • no other form of addiction or disability costs the US pp. 231-261 more than alcohol use/abuse annually Excessive alcohol use causes 88,000 deaths annually (chapter eight) twice as many as illicit drugs • lost work time, illness, insurance, accidents, medical costs take a toll on all of us…25% of all medical costs in the US are alcohol related Alcohol: The world’s most what is alcohol? dangerous drug? 13th, pp. 239-240; 12th pp. 232-233 The Lancet Medical Journal - 1 November, 2016 • alcohol is a byproduct of fermentation • In a recent article published in of vegetable or fruit pulp or ‘mash’ the British medical journal The this produces a concentration of Lancet, when considering the alcohol up to 14% drug’s damage to: • distillation is a further process by •one’s self capturing the vapors from heating • one’s family the mash, and mix this with water • the environment • proof is the measure of % of alcohol, which means the % • economic cost of alcohol is half of the ‘proof rating’ • Alcohol is the world’s most • some alcohol is 152 proof, or 71% alcohol most beers are damaging drug to individuals 8 proof, or 4% alcohol. -
Zerohack Zer0pwn Youranonnews Yevgeniy Anikin Yes Men
Zerohack Zer0Pwn YourAnonNews Yevgeniy Anikin Yes Men YamaTough Xtreme x-Leader xenu xen0nymous www.oem.com.mx www.nytimes.com/pages/world/asia/index.html www.informador.com.mx www.futuregov.asia www.cronica.com.mx www.asiapacificsecuritymagazine.com Worm Wolfy Withdrawal* WillyFoReal Wikileaks IRC 88.80.16.13/9999 IRC Channel WikiLeaks WiiSpellWhy whitekidney Wells Fargo weed WallRoad w0rmware Vulnerability Vladislav Khorokhorin Visa Inc. Virus Virgin Islands "Viewpointe Archive Services, LLC" Versability Verizon Venezuela Vegas Vatican City USB US Trust US Bankcorp Uruguay Uran0n unusedcrayon United Kingdom UnicormCr3w unfittoprint unelected.org UndisclosedAnon Ukraine UGNazi ua_musti_1905 U.S. Bankcorp TYLER Turkey trosec113 Trojan Horse Trojan Trivette TriCk Tribalzer0 Transnistria transaction Traitor traffic court Tradecraft Trade Secrets "Total System Services, Inc." Topiary Top Secret Tom Stracener TibitXimer Thumb Drive Thomson Reuters TheWikiBoat thepeoplescause the_infecti0n The Unknowns The UnderTaker The Syrian electronic army The Jokerhack Thailand ThaCosmo th3j35t3r testeux1 TEST Telecomix TehWongZ Teddy Bigglesworth TeaMp0isoN TeamHav0k Team Ghost Shell Team Digi7al tdl4 taxes TARP tango down Tampa Tammy Shapiro Taiwan Tabu T0x1c t0wN T.A.R.P. Syrian Electronic Army syndiv Symantec Corporation Switzerland Swingers Club SWIFT Sweden Swan SwaggSec Swagg Security "SunGard Data Systems, Inc." Stuxnet Stringer Streamroller Stole* Sterlok SteelAnne st0rm SQLi Spyware Spying Spydevilz Spy Camera Sposed Spook Spoofing Splendide -
Recommendation from the Scientific Committee on Occupational Exposure Limits for Cyanamide
Recommendation from the Scientific Committee on Occupational Exposure Limits for Cyanamide SCOEL/SUM/100_rev September 2003 European Commission Employment, Social Affairs and Inclusion Recommendation from the Scientific Committee on Occupational Exposure Limits for cyanamide Table of Contents 1. Occurrence / Use ........................................................................................................................... 4 2. Health significance......................................................................................................................... 4 2.1. Metabolism and toxicokinetics..............................................................................................4 2.2. Acute toxicity ........................................................................................................................... 4 2.3. Sensitisation............................................................................................................................... 5 2.4. Toxicity after repeated exposure .......................................................................................... 5 2.5. Reproductive toxicity .............................................................................................................. 6 2.6. Genotoxicity ............................................................................................................................. 7 2.7. Carcinogenicity ...................................................................................................................... -
Recovery Center of America
CERTIFICATE OF NEED APPLICATION INTERMEDIATE CARE FACILITY 4620 Melwood Road Upper Marlboro, Maryland Applicant: 4620 Melwood Road OPCO, LLC March 27, 2015 Table of Contents Page PART I - PROJECT IDENTIFICATION AND GENERAL INFORMATION ................................... 1 1. FACILITY ............................................................................................................ 1 2. NAME OF OWNER ............................................................................................. 1 3. APPLICANT ........................................................................................................ 1 4. NAME OF LICENSEE OR PROPOSED LICENSEE ........................................... 2 5. LEGAL STRUCTURE OF APPLICANT ............................................................... 2 6. PERSON(S) TO WHOM QUESTIONS REGARDING THIS APPLICATION SHOULD BE DIRECTED ............................................................ 2 7. TYPE OF PROJECT ........................................................................................... 4 8. PROJECT DESCRIPTION .................................................................................. 4 A. Executive Summary of the Project ........................................................... 4 B. Comprehensive Project Description ......................................................... 5 9. BED INVENTORY ..............................................................................................14 10. COMMUNITY BASED SERVICES .....................................................................14 -
Phenomenology Epidemiology
Phenomenology DEFINITIONS Intoxication: reversible, substance-specific physiological and behavioral changes due to recent exposure to a psychoactive substance. Addiction: compulsion to use a drug, usually for its psychic, rather than therapeutic, effects Tolerance: the decline in potency of an opioid experienced with continued use, so that higher doses are needed to achieve the same effect. This is a receptor mediated effect, typical of many psychoactive drugs. Physical Dependence: refers to the development of withdrawal symptoms once a drug is stopped. Withdrawal: a physiological state that follows cessation or reduction in the amount of a drug used. Generally these effects are the opposite of the drugs normal effects. Substance Dependence (DSM version): A maladaptive pattern of substance use with adverse clinical consequences. Substance Abuse (DSM version): A maladaptive pattern of use that causes clinically significant impairment. Alcoholism: A repetitive, but inconsistent and sometimes unpredictable loss of control of drinking which produces symptoms of serious dysfunction or disability. Clearly there is a wide range of findings possible on the mental status exam, however any exam should look for typical signs of regular substance use. Epidemiology Use of psychoactive substances is common in society, and is often socially acceptable or at least tolerated. Historically, psychoactive substance has served a variety of purposes, including medicinal, social, recreational and religious. In the U.S., 90% people report some alcohol use, 80% report some caffeine use, 25% report use of tobacco products, and 37% report having used illicit substances (at least once in life). Dependence and Abuse are also very common (13.6% in ECA). Over 10 million Americans are alcoholics, over 8 million are "Problem drinkers." Only 3% of alcoholics are on skid row. -
COVID-19 and Alcoholism: a Dangerous Synergy?
Journal of Contemporary Studies in Epidemiology and Public Health 2020, 1(1), ep20002 ISSN 2634-8543 (Online) https://www.jconseph.com/ Review Article OPEN ACCESS COVID-19 and Alcoholism: A Dangerous Synergy? Ademola Samuel Ojo 1* , Ayotemide Akin-Onitolo 2 , Paul Okediji 3 , Simon Balogun 4 1 St George’s University School of Medicine, GRENADA 2 Solina Center for International Development and Research, Abuja, NIGERIA 3 Synberg Research & Analytics, Abuja, NIGERIA 4 Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife, NIGERIA *Corresponding Author: [email protected] Citation: Ojo AS, Akin-Onitolo A, Okediji P, Balogun S. COVID-19 and Alcoholism: A Dangerous Synergy?. Journal of Contemporary Studies in Epidemiology and Public Health. 2020;1(1):ep20002. https://doi.org/10.30935/jconseph/8441 ABSTRACT The 2019 novel coronavirus disease (COVID-19) has triggered the world’s worst public health challenge in the last 100 years. In response, many countries have implemented disease control measures such as enforced quarantine and travel restrictions. These measures have inadvertent adverse effects on the mental health and psyche of populations. Long-term social isolation is associated with alcohol use and misuse, creating a potential public health crisis. Alcohol and its intermediate products of metabolism have a multisystemic effect with an impact on the liver, heart, lungs as well as other organs in the body. Similarly, COVID-19 mediate a damaging effect on organ systems through cytopathic effects and cytokine storm. Alcoholism potentially increases the risk of cardiac injury, acute respiratory distress syndrome, pulmonary fibrosis, and liver damage in synergy with COVID-19; thereby worsening disease prognosis and outcome. -
The Effect of Alcohol Consumption on Risk for Sepsis and ARDS
The Effect of Alcohol Consumption on Risk for Sepsis and ARDS E. L. Burnham, M. Moss, and G. S. Martin I Introduction Alcohol is the most frequently abused drug throughout the world, and alcohol-re lated problems are a common occurrence among patients admitted to hospitals and intensive care units (ICUs). Alcohol affects all tissues of the body. Its effects on im mune function and the systemic inflammatory response syndrome (SIRS) remain topics of active investigation. In regard to immune function, alcohol consumption alters the response at several points along the inflammatory cascade. Due to these potent modulating effects on immune function, alcoholic patients have an increased incidence and severity of infection, particularly in the lung. This association be tween alcohol use and infection is especially evident in the post-operative setting. Among patients with sepsis, a prior history of chronic alcohol abuse confers a sig nificant increase in the likelihood of respiratory dysfunction and development of acute respiratory distress syndrome (ARDS). Chronic alcohol abuse similarly in creases the mortality from ARDS. One possible mechanism by which chronic alco hol abuse may increase susceptibility to acute lung injury (ALI} is through altera tions in pulmonary glutathione homeostasis. This chapter discusses the immuno modulatory effects of alcohol and the epidemiological and experimental evidence associating chronic alcohol abuse, sepsis, and the development of ARDS. I Background Alcohol is the most commonly abused drug in the world, with approximately half the US population consuming alcohol regularly. Fifteen to twenty million individuals meet the criteria for alcoholism [ 1]. The economic cost of alcohol in the USA is around $100 billion (USD), with > 10% of this cost directly attributable to medical services [2].